score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G990D	0.0651	292.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				PDGFRA p.G990D (Missense)	0.0	MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat21		
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.N2326K	0.0504	119.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.N2326K (Missense)	1.0	MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R343C	0.6429	14.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0.0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75	0				POLD1 p.R343C (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1062L	0.0782	243.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				CDK12 p.P1062L (Missense)	0.0	MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S1132F	0.0779	308.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				TET2 p.S1132F (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P3320S	0.1395	215.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.P3320S (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E167K	0.0543	184.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616						0				NFE2L2 p.E167K (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.P74L	0.1429	28.0	1.7e-05	0.0																Investigate Actionability	1.0	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0				RBM10 p.P74L (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P141L	0.1935	62.0	0.0	0.0																					0				NTRK3 p.P141L (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.0577	468.0	0.0	0.0																					0				NF1 p.R440* (Nonsense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Biologically Relevant				Somatic Variant	COL1A1	Splice Site		0.0521	96.0	0.0	0.0																					0				COL1A1  (Splice Site)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Biologically Relevant				Somatic Variant	ERG	Missense	p.G390E	0.0842	190.0	0.0	0.0																					0				ERG p.G390E (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P21L	0.0556	54.0	0.0	0.0																					0				LIMK2 p.P21L (Missense)		MEL-IPI_Pat21	MEL-IPI_Pat21-Tumor-SM-4DK1H	MEL-IPI_Pat21-Normal-SM-53U5G
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat21		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.804																									0				COSMIC Signature (version 2) 7 (80%)		MEL-IPI_Pat21		
